SCHEMBL6099648

SCHEMBL6099648

CC(C)CNc1c([N+](=O)[O-])c2nnnn2c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.45
HPGD P15428 5/20 0.45
MAPT P10636 7/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 2/20 0.40
HTT P42858 1/20 0.40
POLB P06746 1/20 0.38
MAPK1 P28482 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
ATM Q13315 1/20 0.37
DPP4 P27487 1/20 0.36
TDP1 Q9NUW8 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TNKS O95271 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7022105 0.86 ALDH1A1 (0.35) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL7025149 0.85 MAPT (0.38) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL6099481 0.83 ALDH1A1 (0.40) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL1960443 0.82 CTSV (0.37) ALDH1A1HPGDMAPTMEN1KMT2A
SCHEMBL6100506 0.81 MAPT (0.47) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL14130986 0.80 KDM4E (0.44) ALDH1A1HPGDMAPTGAAHTT
SCHEMBL14143504 0.80 MAPT (0.36) ALDH1A1HPGDMAPTGAAPOLB
SCHEMBL8307224 0.77 MAPT (0.42) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL6106397 0.74 ALDH1A1 (0.51) ALDH1A1HPGDMAPTLMNAGAA
SCHEMBL6097459 0.74 S100A4 (0.47) ALDH1A1HPGDMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2008-07-03 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-7301027-B2 Process for the preparation of Imiquimod and intermediates thereof DIPHARMA S.P.A. (IT) 2007-11-27 US disclosed
US-7026482-B2 Process for preparing imidazoquinolinamines MEDICIS PHARMACEUTICAL CORPORATION 2006-04-11 US disclosed
US-6897314-B2 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-05-24 US disclosed
US-20050096470-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2005-05-05 US disclosed
EP-0912565-B1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING & MFG (US) 2004-04-14 EP disclosed
US-20040019213-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2004-01-29 US disclosed
US-6624305-B2 Reacting a 6H-imidazo(4,5-c) tetrazolo(1,5-a)quinoline with triphenylphosphine and hydrolyzing 3M INNOVATIVE PROPERTIES COMPANY 2003-09-23 US disclosed
US-6613902-B2 Induce biosynthesis of cytokines such as interferons, interleukins, and tumor necrosis factor in humans and in mice. 3M INNOVATIVE PROPERTIES COMPANY 2003-09-02 US disclosed
US-20030153762-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2003-08-14 US disclosed
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES 3M INNOVATIVE PROPERTIES COMPANY 2003-07-10 US disclosed
US-6534654-B2 Providing a tetrazole(1,5-a)quinolin-5-ol and nitrating the compound to form 4-nitrotetrazole(1,5-a)quinoline-5-ol, sulfonylating at 5-position, reacting with an amine to form a 5-amine derivative, further reducing to form 4,5-daimines 3M INNOVATIVE PROPERTIES COMPANY 2003-03-18 US disclosed
US-20020188127-A1 Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY 2002-12-12 US disclosed
US-6437131-B1 REACTING A 6H-IMIDAZO(4,5-C)TETRAZOLO(1,5-A)QUINOLINE WITH TRIPHENYLPHOSPHINE, HYDROLYZING TO FORM 1H-IMIDAZO(4,5-C) QUINOLIN-4-AMINES; INTERMEDIATE IS A 4-NITROTETRAZOLO(1,5-A) QUINOLIN-5-SULFONATE IN THE PR 3M INNOVATIVE PROPERTIES COMPANY 2002-08-20 US disclosed
US-6150523-A Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-11-21 US disclosed
US-5998619-A Process for preparing imidazoquinolinamines 3M INNOVATIVE PROPERTIES COMPANY (US) 1999-12-07 US disclosed
EP-0912565-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1999-05-06 EP disclosed
US-5741908-A Process for reparing imidazoquinolinamines MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1998-04-21 US disclosed
WO-1997048704-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1997-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161573-A1 PROCESS FOR THE PREPARATION OF IMIQUIMOD AND INTERMEDIATES THEREOF MYD88, TLR7, MAVS ALDH1A1 315/4885HPGD 308/4885MAPT 4284/4885
US-20040019213-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 ALDH1A1 1648/4885HPGD 2419/4885MAPT 3519/4885
US-20050096470-A1 Process for preparing imidazoquinolinamines ITPA, INMT, PIP4K2C ALDH1A1 1777/4885HPGD 2114/4885MAPT 3755/4885
US-20020188127-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 ALDH1A1 1648/4885HPGD 2419/4885MAPT 3519/4885
US-20030130516-A1 PROCESS FOR PREPARING IMIDAZOQUINOLINAMINES VAT1, QARS1, TALDO1 ALDH1A1 1648/4885HPGD 2419/4885MAPT 3519/4885
US-20030153762-A1 Process for preparing imidazoquinolinamines VAT1, QARS1, TALDO1 ALDH1A1 1648/4885HPGD 2419/4885MAPT 3519/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.